Forum Markets, Incorporated · NASDAQ:FRMM
Forum Markets — 180 Life Sciences — Investor Presentation (February 2023)
17 slides from Forum Markets's investor presentation, Feb 16, 2023
Slide 1: Leading Research into Solving One of the World's Largest Drivers of Disease: Inflammation
180 Life Sciences Corp. www.180lifesciences.com Corporate Presentation February 2023 Leading Research into Solving One of the World’s Largest Drivers of Disease: INFLAMMATION NASDAQ: ATNF
Slide 2: Disclaimer and Forward-Looking Statements
180 Life Sciences Corp. www.180lifesciences.com This Presentation is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other financial instruments of 180 LIFE SCIENCES Corp . (“ 180 Life Sc
Slide 3: 180 Life Sciences Overview
180 Life Sciences Corp. www.180lifesciences.com 180 Life Sciences Overview Leading Research into Solving One of the World’s Largest Drivers of Disease: INFLAMMATION 3 Robust IP - Protected Product Pipeline with Large Market Potential • Three families of novel drugs address significant market opportu
Slide 4: Three Therapeutic Families Targeting Multiple Indications
180 Life Sciences Corp. www.180lifesciences.com 4 Three Therapeutic Families Targeting Multiple Indications Indication Early - Stage Development Late - Stage Development Milestones Discovery/Validation Phase 1 Phase 2 Phase 3 Fibrosis & Anti - TNF* Dupuytren’s Contracture Pursuing Conditional Market
Slide 5: Experienced Leadership Team, Founders and Board of Directors
180 Life Sciences Corp. www.180lifesciences.com 5 Frank Knuettel II, MBA Independent Director Pamela Marrone, PhD Independent Director Prof. Larry Gold, PhD Independent Director Donald McGovern, Jr. Independent Director Russell Ray, MBA Independent Director Teresa DeLuca, MD, MBA Independent Directo
Slide 6: Fibrosis & Anti-TNF Therapeutics: Lead Clinical Indications
180 Life Sciences Corp. www.180lifesciences.com Fibrosis & Anti - TNF Therapeutics: Lead Clinical Indications Novel Treatments for TNF - Driven Conditions Dupuytren’s Contracture Frozen Shoulder POCD 6 • All three conditions are primarily driven by a pro - inflammatory protein called tumor necrosis
Slide 7: Initial Indication Targeting Dupuytren's Contracture
180 Life Sciences Corp. www.180lifesciences.com Characteristics • Common localized fibrotic condition of the hand , develops over years • Nodules form under skin – eventually creating a thick cord pulling one or more fingers • Can limit hand functions • Unlike liver and lung fibrosis, can be identif
Slide 8: Phase 2a Completed: 40mg Adalimumab is Effective
180 Life Sciences Corp. www.180lifesciences.com Phase 2a Completed: 40mg (in 0.4ml) Adalimumab is Effective • Dose ranging with 28 patients • 40 mg in 0.4ml – effective dose • Funded by HICF (Wellcome Trust + Dept of Health) and 180 Life Sciences Trial Overview Adalimumab injected directly into the
Slide 9: Phase 2b Trial Design
180 Life Sciences Corp. www.180lifesciences.com optimal dose of adalimumab: four 40mg injections in 0.4mL at baseline placebo Primary Endpoint: nodule hardness at 12 months measured with a durometer Month first dose 3 6 9 Secondary Endpoint: n odule size measured using an ultrasound scan at 12 and 1
Slide 10: Phase 2b: Primary and Key Secondary Endpoint Met
180 Life Sciences Corp. www.180lifesciences.com p=0002 p<0.0001 p<0.0001 p=0.025 Results were clinically significant vs. placebo Phase 2b: Primary and Key Secondary Endpoint Met Endpoints selected as reductions potentially indicate disease no longer progressing Nodule hardness - 4.6 AU at 12 months
Slide 11: Early-Stage Dupuytren's Contracture Prevalence
180 Life Sciences Corp. www.180lifesciences.com 11 Early - Stage Dupuytren’s Contracture Prevalence 11 ~32.5M Patients with Early - Stage Dupuytren’s Contracture (U.S., U.K., EU) ~12M U.S. Prevalence ~2.5M U.K. Prevalence ~18M EU Prevalence Approximately 20 - 35% of patients with a palmar nodule pro
Slide 12: Post Operative Delirium/Cognitive Deficit (POCD) and Frozen Shoulder
180 Life Sciences Corp. www.180lifesciences.com • Over 300,000 hip fractures each year in the US alone (1) • Strong clinical evidence for anti - TNF as preventative therapy • Patent claims granted, patent is licensed from Kennedy Trust, UK • Phase 2 multi - center trial of pre - operative anti - TNF
Slide 13: SCA Family: Synthetic CBD Analogs for Pain & Inflammation
180 Life Sciences Corp. www.180lifesciences.com SCA Family: Synthetic CBD Analogs for Pain & Inflammation • Safe & non - psychoactive • Formulated to offer improved oral bioavailability (>3x) • Rigorously tested in clinical trials for inflammatory pain (efficacy and dosing) • Granted market approval
Slide 14: a7nAChR Family: Novel Platform for Ulcerative Colitis
180 Life Sciences Corp. www.180lifesciences.com a7nAChR Family: Novel Platform for Ulcerative Colitis a7nAChR is a nicotine acetylcholine receptor and a central factor in evolutionarily ancient neural circuit to control of inflammation (1,2) (1) Rothbard JB et al. Identification of a common immune r
Slide 15: Advancing Multiple Programs into the Clinic
180 Life Sciences Corp. www.180lifesciences.com Advancing Multiple Programs into the Clinic Indication 2022 2023 2024 Fibrosis & Anti - TNF* Dupuytren’s Contracture 1H Phase 2b POC data 2H Consult with regulatory authorities to determine approval pathway Frozen Shoulder 2H Initiated Phase 2 Q1 2024
Slide 16: 180 Life Sciences Highlights
180 Life Sciences Corp. www.180lifesciences.com 16 180 Life Sciences Highlights Leading Research into Solving One of the World’s Largest Drivers of Disease: INFLAMMATION 16 Robust IP - Protected Product Pipeline with Large Market Potential Scientific Pioneers Backed by Experienced Operators and Boar
Slide 17: Thank you
180 Life Sciences Corp. www.180lifesciences.com www.180lifesciences.com Thank you 17
180 Life Sciences — Investor Presentation (February 2023) on 6ix